Role of c-MET in upper aerodigestive malignancies - From biology to novel therapies

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 24, Issue 3, 2005, Pages 149-162

  Dietrich, Sascha ^b   Uppalapati, Radha ^b   Seiwert, Tanguy Y ^a   Ma, Patrick C ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b NONE

Author keywords

c MET; Carcinogenesis; Cell migration; Cell scattering; Hepatocyte growth factor scatter factor (HGF SF); Protooncogenes; Receptor tyrosine kinase (RTK); Signal transduction; Upper aerodigestive cancer

Indexed keywords

ANTINEOPLASTIC AGENT; ERLOTINIB; GEFITINIB; IMATINIB; LIGAND; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MESYLIC ACID; MONOCLONAL ANTIBODY; PHA 665752; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; REACTIVE OXYGEN METABOLITE; RIBOZYME; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SMALL INTERFERING RNA; SU 11274; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; BRANCHING MORPHOGENESIS; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; DRUG TARGETING; ESOPHAGUS CANCER; GENE ACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; METASTASIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTO ONCOGENE; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; ESOPHAGUS TUMOR; GENETICS; LUNG TUMOR; METABOLISM; MOUSE; MUTATION; SMALL CELL CARCINOMA; SQUAMOUS CELL CARCINOMA;

MAMMALIA;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; DISEASE MODELS, ANIMAL; ESOPHAGEAL NEOPLASMS; HUMANS; LUNG NEOPLASMS; MICE; MUTATION; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION;

EID: 25144439139     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: 10.1615/JEnvPathToxOncol.v24.i3.20     Document Type: Review

References (59)

1. Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 2003;22(4): 309-25.
2. Cooper CS, Park M, Blair DG, Tainsky MA, Huebner K, Croce CM, et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature. 1984;311(5981):29-33.
3. Park M, Dean M, Cooper CS, Schmidt M, O'Brien SJ, Blair DG, et al. Mechanism of met oncogene activation. Cell. 1986;45(6):895-904.
4. Naldini L, Weidner KM, Vigna E, Gaudino G, Bardelli A, Ponzetto C, et al. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J. 1991;10(10):2867-78.
5. Antipenko A, Himanen JP, van Leyen K, NardiDei V, Lesniak J, Barton WA, et al. Structure of the semaphorin-3A receptor binding module. Neuron. 2003;39(4):589-98.
6. Love CA, Harlos K, Mavaddat N, Davis SJ, Stuart DI, Jones EY, et al. The ligand-binding face of the semaphorins revealed by the high-resolution crystal structure of SEMA4D. Nat Struct Biol. 2003;10(10):843-8.
7. Stamos J, Lazarus RA, Yao X, Kirchhofer D, Wiesmann C. Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor. EMBO J. 2004;23(12):2325-35.
8. Stella MC, Comoglio PM. HGF: a multifunctional growth factor controlling cell scattering. Int J Biochem Cell Biol. 1999;31(12):1357-62.
9. Comoglio PM. Pathway specificity for Met signalling. Nat Cell Biol. 2001;3(7):E161-2.
10. Muller M, Morotti A, Ponzetto C. Activation of NF-kappaB is essential for hepatocyte growth factor-mediated proliferation and tubulogenesis. Mol Cell Biol. 2002;22(4):1060-72.
11. Maulik G, Kijima T, Ma PC, Ghosh SK, Lin J, Shapiro GI, et al. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res. 2002;8(2):620-7.
12. Nobes CD, Hall A. Rho, rac and cdc42 GTPases: regulators of actin structures, cell adhesion and motility. Biochem Soc Trans. 1995;23(3):456-9.
13. Maulik G, Madhiwala P, Brooks S, Ma PC, Kijima T, Tibaldi EV, et al. Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer. J Cell Mol Med. 2002;6(4):539-53.
14. Derman MP, Chen JY, Spokes KC, Songyang Z, Cantley LG. An 11-amino acid sequence from c-met initiates epithelial chemotaxis via phosphatidylinositol 3-kinase and phospholipase C. J Biol Chem. 1996;271(8):4251-5.
15. Besser D, Bardelli A, Didichenko S, Thelen M, Comoglio PM, Ponzetto C, et al. Regulation of the urokinase-type plasminogen activator gene by the oncogene Tpr-Met involves GRB2. Oncogene. 1997;14(6):705-11.
16. Dunsmore SE, Rubin JS, Kovacs SO, Chedid M, Parks WC, Welgus HG. Mechanisms of hepatocyte growth factor stimulation of keratinocyte metalloproteinase production. J Biol Chem. 1996;271(40): 24576-82.
17. Wojta J, Nakamura T, Fabry A, Hufnagl P, Beckmann R, McGrath K, et al. Hepatocyte growth factor stimulates expression of plasminogen activator inhibitor type 1 and tissue factor in HepG2 cells. Blood. 1994;84(1):151-7.
18. Bardelli A, Basile ML, Audero E, Giordano S, Wennstrom S, Menard S, et al. Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis. Oncogene. 1999;18(5):1139-46.
19. Saucier C, Papavasiliou V, Palazzo A, Naujokas MA, Kremer R, Park M. Use of signal specific receptor tyrosine kinase oncoproteins reveals that pathways downstream from Grb2 or Shc are sufficient for cell transformation and metastasis. Oncogene. 2002;21(12):1800-11.
20. Birchmeier C, Gherardi E. Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol. 1998;8(10):404-10.
21. Uehara Y, Minowa O, Mori C, Shiota K, Kuno J, Noda T, et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/ scatter factor. Nature. 1995;373(6516):702-5.
22. Schmidt C, Bladt F, Goedecke S, Brinkmann V, Zschiesche W, Sharpe M, et al. Scatter factor/ hepatocyte growth factor is essential for liver development. Nature. 1995;373(6516):699-702.
23. Maina F, Casagranda F, Audero E, Simeone A, Comoglio PM, Klein R, et al. Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development. Cell. 1996;87(3): 531-42.
24. Maina F, Klein R. Hepatocyte growth factor, a versatile signal for developing neurons. Nat Neurosci. 1999;2(3):213-7.
25. Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD, et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 2003;63(19):6272-81.
26. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997;16(1):68-73.
27. Schmidt L, Junker K, Weirich G, Glenn G, Choyke P, Lubensky I, et al. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res. 1998;58(8):1719-22.
28. Schmidt L, Junker K, Nakaigawa N, Kinjerski T, Weirich G, Miller M, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene. 1999;18(14):2343-50.
29. Miller M, Ginalski K, Lesyng B, Nakaigawa N, Schmidt L, Zbar B. Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: modeling studies. Proteins. 2001;44(1):32-43.
30. Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 2005;65(4):1479-88.
31. Lorenzato A, Olivero M, Patane S, Rosso E, Oliaro A, Comoglio PM, et al. Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. Cancer Res. 2002;62(23):7025-30.
32. Tolnay E, Kuhnen C, Wiethege T, Konig JE, Voss B, Muller KM. Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma. J Cancer Res Clin Oncol. 1998;124(6):291-6.
33. Harvey P, Clark IM, Jaurand MC, Warn RM, Edwards DR. Hepatocyte growth factor/scatter factor enhances the invasion of mesothelioma cell lines and the expression of matrix metalloproteinases. Br J Cancer. 2000;83(9):1147-53.
34. Harvey P, Warn A, Dobbin S, Arakaki N, Daikuhara Y, Jaurand MC, et al. Expression of HGF/SF in mesothelioma cell lines and its effects on cell motility, proliferation and morphology. Br J Cancer. 1998;77(7):1052-9.
35. Klominek J, Baskin B, Liu Z, Hauzenberger D. Hepatocyte growth factor/scatter factor stimulates chemotaxis and growth of malignant mesothelioma cells through c-met receptor. Int J Cancer. 1998;76(2):240-9.
36. Lo Muzio L, Leonardi R, Mignogna MD, Pannone G, Rubini C, Pieramici T, et al. Scatter factor receptor (c-Met) as possible prognostic factor in patients with oral squamous cell carcinoma. Anticancer Res. 2004;24(2C):1063-9.
37. Morello S, Olivero M, Aimetti M, Bernardi M, Berrone S, Di Renzo MF, et al. MET receptor is overexpressed but not mutated in oral squamous cell carcinomas. J Cell Physiol. 2001;189(3): 285-90.
38. Aebersold DM, Landt O, Berthou S, Gruber G, Beer KT, Greiner RH, et al. Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx. Oncogene. 2003;22(52):8519-23.
39. Hu YC, Lam KY, Law S, Wong J, Srivastava G. Profiling of differentially expressed cancer-related genes in esophageal squamous cell carcinoma (ESCC) using human cancer cDNA arrays: overexpression of oncogene MET correlates with tumor differentiation in ESCC. Clin Cancer Res. 2001;7(11):3519-25.
40. Herrera LJ, El-Hefnawy T, Queiroz de Oliveira PE, Raja S, Finkelstein S, Gooding W, et al. The HGF receptor c-Met is overexpressed in esophageal adenocarcinoma. Neoplasia. 2005;7(1):75-84.
41. Graveel CR, London CA, Vande Woude GF. A mouse model of activating Met mutations. Cell Cycle. 2005;4(4):518-20.
42. Graveel C, Su Y, Koeman J, Wang LM, Tessarollo L, Fiscella M, et al. Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. Proc Natl Acad Sci USA. 2004;101(49):17198- 203.
43. Jiang WG, Grimshaw D, Lane J, Martin TA, Abounader R, Laterra J, et al. A hammerhead ribozyme suppresses expression of hepatocyte growth factor/scatter factor receptor c-MET and reduces migration and invasiveness of breast cancer cells. Clin Cancer Res. 2001;7(8):2555-62.
44. Abounader R, Ranganathan S, Lal B, Fielding K, Book A, Dietz H, et al. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. J Natl Cancer Inst. 1999;91(18):1548-56.
45. Abounader R, Lal B, Luddy C, Koe G, Davidson B, Rosen EM, et al. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J. 2002;16(1):108-10.
46. Kim SJ, Johnson M, Koterba K, Herynk MH, Uehara H, Gallick GE. Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model. Clin Cancer Res. 2003;9(14): 5161-70.
47. Bhargava M, Joseph A, Knesel J, Halaban R, Li Y, Pang S, et al. Scatter factor and hepatocyte growth factor: activities, properties, and mechanism. Cell Growth Differ. 1992;3(1):11-20.
48. Zhang YW, Su Y, Lanning N, Gustafson M, Shinomiya N, Zhao P, et al. Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor. Oncogene. 2005;24(1):101-6.
49. Kong-Beltran M, Stamos J, Wickramasinghe D. The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell. 2004;6(1):75-84.
50. Michieli P, Mazzone M, Basilico C, Cavassa S, Sottile A, Naldini L, et al. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell. 2004;6(1):61-73.
51. Sattler M, Pride YB, Ma P, Gramlich JL, Chu SC, Quinnan LA, et al. A novel small molecule MET inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res. 2003;63(17):5462-9.
52. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res. 2003;63(21): 7345-55.
53. Wang X, Le P, Liang C, Chan J, Kiewlich D, Miller T, et al. Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Mol Cancer Ther. 2003;2(11):1085-92.
54. Ma PC, Schaefer E, Christensen JG, Salgia R. A selective small molecule c-MET inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res. 2005;11(6):2312-9.
55. Cao B, Su Y, Oskarsson M, Zhao P, Kort EJ, Fisher RJ, et al. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci USA. 2001;98(13):7443-8.
56. Tomioka D, Maehara N, Kuba K, Mizumoto K, Tanaka M, Matsumoto K, et al. Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model. Cancer Res. 2001;61(20):7518-24.
57. Hirao S, Yamada Y, Koyama F, Fujimoto H, Takahama Y, Ueno M, et al. Tumor suppression effect using NK4, a molecule acting as an antagonist of HGF, on human gastric carcinomas. Cancer Gene Ther. 2002;9(8):700-7.
58. Di Renzo MF, Olivero M, Martone T, Maffe A, Maggiora P, Stefani AD, et al. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene. 2000;19(12):1547-55.
59. Jeffers M, Schmidt L, Nakaigawa N, Webb CP, Weirich G, Kishida T, et al. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci USA. 1997;94(21): 11445-0.